10 Under-the-Radar Healthcare Stocks With Incredible Growth Potential
Key Takeaways
There's a strong case that healthcare is the most important sector in the stock market. These companies der innovative therapies and medical nologies that are often life-saving. Investors stand to...
Article Overview
Quick insights and key information
4 min read
Estimated completion
investment
Article classification
June 28, 2025
09:10 AM
The Motley Fool
Original publisher
There's a strong case that healthcare is the most important sector in the stock market
These companies der innovative therapies and medical nologies that are often life-saving
Investors stand to benefit as healthcare leaders and emerging players address the needs of an aging global population and the rising prevalence of chronic diseases
Here are 10 under-the-radar healthcare stocks that could be great buys for your portfolio
Image source: Getty Images
Certara Certara (CERT -0. 22%) is poised to capitalize on the transformation in medicine driven by artificial intelligence (AI), viding bio-simulation software and services that accelerate drug development
The company plays a crucial role in the pharmaceutical industry
Over 90% of all novel drugs apved by the Food and Drug Administration (FDA) since 2014 have leveraged its nology
Its AI-driven solutions enhance re and development (R&D), enabling faster and more precise drug development
Certara deserves a closer look by investors seeking to tap into the AI-driven healthcare transformation
Beam Therapeutics Beam Therapeutics (BEAM -1. 98%) is a clinical-stage bio pioneering precision-based gene editing therapies for genetic diseases, including sickle cell disease
Its innovative nology enables precise single-nucleotide DNA changes, potentially offering a safer alternative to traditional CRISPR genetic engineering
Beam has reported early success in gene correction, with its lead candidate, BEAM-101, in phase 1/2 trials for sickle cell disease
While the company still has a lot to ve, its differentiated apach and clinical gress position it for remarkable growth in the long term
Inspire Medical Systems Inspire Medical Systems (INSP 2. 08%) develops implantable neurostimulation devices for obstructive sleep apnea, offering its FDA-apved Inspire therapy as a noninvasive alternative to CPAP machines
In its first quarter (the period March 31), revenue surged 23% year over year to $201 million, driven by growing U
Adoption and new international apvals
With increasing demand for sleep apnea treatment, Inspire has a significant opportunity to capture market
Insulet Insulet (PODD 1. 03%) specializes in tubeless insulin pump nology
Its Omnipod system simplifies diabetes management for Type 1 and insulin-dependent Type 2 patients globally, offering convenience and imved outcomes
With a 2025 revenue growth target of 19% to 22%, the company is poised for continued expansion, particularly in underpenetrated international
Insulet's strong growth trajectory positions it to reward holders further
Krystal Bio Krystal Bio (KRYS -2. 60%) focuses on rare skin diseases
Its FDA-apved gene therapy, Vyjuvek, for dystrophic epidermolysis bullosa (fragile skin that blisters easily) is expected to apach $400 million in revenue this year, solidifying its position as a best-in-class treatment
Vyjuvek's success validates Krystal's R&D, bolstering confidence in its pipeline and unlocking added market potential
LifeMD LifeMD (LFMD 1. 33%) operates a telehealth platform viding specialized virtual care in weight loss, men's health, and dermatology
A partnership with Novo Nordisk to offer Wegovy, a leading GLP-1 treatment, has driven impressive growth, with first-quarter revenue surging 49% year over year for the period March 31
LifeMD could expand its growing user base into a comprehensive health management ecosystem to fuel growth and solidify its telehealth leadership
Option Care Health Option Care Health (OPCH 0. 78%) is the leading U
Vider of and alternative-site infusion services, dering crucial therapies for chronic and acute conditions cancer, immune deficiencies, and infections
As the healthcare industry shifts toward more personalized and cost-effective care, Option Care Health is in position to capitalize on the strong demand, with its extensive network and high-quality services
Tempus AI Tempus AI (TEM -2. 69%) harnesses artificial intelligence to advance precision medicine, using its collection of clinical and molecular data from more than 40 million patients to power diagnostics in oncology, cardiology, and beyond
The company jects its revenue to climb by more than 80% this year, to $1
Tempus AI's scalable platform and extensive data ecosystem present substantial opportunities for expansion and impact in personalized healthcare
TransMedics Group TransMedics Group (TMDX 1. 08%) has revolutionized organ transplantation with its Organ Care System (OCS), the only FDA-apved device for heart, lung, and r transplants that extends organ preservation time
The company's jected revenue growth of 30% this year underscores the strong momentum in a global expansion opportunity
Veeva Systems Veeva Systems (VEEV 0. 60%) offers cloud-based software that lines clinical, regulatory, and commercial cesses for life sciences companies
Serving over 1,000 customers, including major pharmaceutical companies and emerging bios, Veeva's platform is well positioned to capitalize on the industry's increasing reliance on digital solutions for innovation and compliance
Dan Victor has no position in any of the stocks mentioned
The Motley Fool has positions in and recommends Beam Therapeutics, Inspire Medical Systems, TransMedics Group, and Veeva Systems
The Motley Fool recommends Insulet, Krystal Bio, and Novo Nordisk
The Motley Fool has a disclosure policy.
Related Articles
More insights from FinancialBooklet